Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...

Large language models (LLMs) may serve as a valuable supplement to oncology documentation workflows by detecting and ...

Heather Stefanski, MD, PhD, representing the National Marrow Donor Program, provides a detailed overview of the ACCESS study ...

Joshua K. Sabari, MD, discusses the highly heterogeneous and aggressive nature of HER2 mutation–positive non–small cell lung ...

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new ...

FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...

In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based ...

Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could ...

The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...

FDA accepted an RTOR sBLA and granted priority review for zanidatamab-hrii combinations as first-line therapy in HER2+ ...

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse ...

Rashmi Chugh, MD, of the University of Michigan, outlines a strategic roadmap for the future development of ozekibart in ...